In order to rationally and effectively develop treatments for multiple myeloma, improved pre-clinicla models are needed. Existing mouse models of myelom are woefully inadequate as they do not acurately simulate the clinical picture in humans. We have developed novel transgenic mice that uses somatic hypermutation to activate an oncogene (myc) and reproducibly develop smouldering myeloma. In addition we have crossed these with mice that are engineered to express acivated FGFR3. In contrast to other models, disease is limitted to the bone marrow. We wish to test this model as a as a pre-clinical screening tool for drugs with efficacy against multiple myeloma. We hypothesize that this model will be a more predictive tool in determining active or inactive drugs in the clinical setting.